21 results
8-K
EX-99.1
OCX
Oncocyte Corporation
23 Jan 24
Regulation FD Disclosure
4:39pm
damage and rejection.
Also, check out our newly designed VitaGraft Kidney web page!
https://hubs.li/Q02hhzvl0
#OCX #Innovation #WhereTomorrowLives … Kidney is now broadly available upon request.
#OCX #Innovation #WhereTomorrowLives
8-K
EX-99.1
OCX
Oncocyte Corporation
9 Aug 18
Seasoned Healthcare Executive Albert P. Parker Appointed
4:10pm
, L.L.P.
“OncoCyte’s focus on creating innovation in liquid biopsies, combined with its lead product DetermaVu, provides for unique strategic
8-K
EX-99.1
OCX
Oncocyte Corporation
7 Oct 21
Oncocyte Appoints Gisela A. Paulsen as Chief Operating Officer
8:05am
background leading large-scale global change management and driving commercial and drug development innovation at global pharmaceutical and diagnostics
8-K
EX-99.1
OCX
Oncocyte Corporation
15 May 24
Oncocyte Reports First Quarter 2024 Financial Results
4:21pm
and central to our mission of developing and providing accessible point of care diagnostics and continuous innovation in transplant rejection monitoring
PRER14A
8u9jxdyg
18 May 20
Preliminary revised proxy
6:06am
PRE 14A
245mf6y96lqpvy
2 Jul 18
Preliminary proxy
5:01pm